Skip to main content

Blackstone Inc.

Source: SEC Form 13F · as of Mar 2026

Blackstone Inc. holds 37 biotech & pharma companies tracked by BioSniper, totaling $156.2M in value as of Mar 2026 (SEC Form 13F).

Companies held

37

Total value held

$156.2M

BioSniper AIPage evidence connected

Prepared research question

What matters most for Autolus Therapeutics plc (AUTL)—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

CompanySharesValue
AUTLAutolus Therapeutics plc20,485,611$28.3M
SYRESpyre Therapeutics, Inc.292,847$14.8M
DMRADamora Therapeutics, Inc.503,522$13.0M
TERNTerns Pharmaceuticals, Inc.231,282$12.2M
ALXOALX ONCOLOGY HOLDINGS INC5,826,544$11.7M
XFORX4 Pharmaceuticals, Inc2,681,922$11.1M
CMPXCompass Therapeutics, Inc.1,857,848$9.8M
DFTXDefinium Therapeutics Inc.508,668$9.6M
ASMBASSEMBLY BIOSCIENCES, INC.296,855$8.2M
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)85,001$4.7M
AXSMAxsome Therapeutics, Inc.24,500$4.1M
SABSSAB BIOTHERAPEUTICS, INC.860,170$3.3M
DNTHDianthus Therapeutics, Inc. /DE/35,045$2.9M
ALNYALNYLAM PHARMACEUTICALS, INC.8,775$2.9M
IMVTImmunovant, Inc.107,297$2.7M
ROIVRoivant Sciences Ltd.92,372$2.6M
FOLDAMICUS THERAPEUTICS, INC.170,209$2.5M
GILDGILEAD SCIENCES, INC.10,577$1.5M
VKTXViking Therapeutics, Inc.35,726$1.2M
STOKStoke Therapeutics, Inc.30,579$996K
LQDALiquidia Corp25,236$952K
DAWNDay One Biopharmaceuticals, Inc.41,567$891K
EXELEXELIXIS, INC.18,901$811K
ARWRARROWHEAD PHARMACEUTICALS, INC.12,796$802K
MAZEMaze Therapeutics, Inc.24,990$746K
PTCTPTC THERAPEUTICS, INC.10,367$706K
MRNAModerna, Inc.12,613$641K
APLSApellis Pharmaceuticals, Inc.12,712$511K
RVMDREVOLUTION MEDICINES, INC.3,539$344K
ACADACADIA PHARMACEUTICALS INC13,293$296K
LGNDLigand Pharmaceuticals Incorporated1,412$282K
PCVXVaxcyte, Inc.4,544$264K
ADMAADMA BIOLOGICS, INC.25,588$231K
RYTMRHYTHM PHARMACEUTICALS, INC.2,600$226K
CYTKCYTOKINETICS INC3,374$222K
ALECAlector, Inc.77,145$166K
PLRXPLIANT THERAPEUTICS, INC.22,206$28K

13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.